<DOC>
	<DOC>NCT02265484</DOC>
	<brief_summary>After successful screening of liver cirrhosis patients attending ILBS OPD for signs of parkinsonism ( tremor, rigidity or bradykinesia, any 2 of 3). Diagnosis of hepatic/cirrhosis related parkinsonism will be made. Patients will be randomized into Bromocriptine and Placebo. Patients will be followed up every month in OPD (Out Patient Department), ILBS (Institute of liver &amp; Biliary Sciences) for 3 months. Detailed neurological examination will be done at each visit &amp; UPDRS (Unified Parkinson's Disease Rating Scale ) score will be calculated.</brief_summary>
	<brief_title>To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<criteria>Patients with cirrhosis of liver with signs of parkinsonisms Patients consented for the study protocol by signing the informed consent. Age &lt; 18 years. Patient s with HCC (Hepatocellular Carcinoma). Patients diagnosed as Wilsons disease. Patient who withdrew or non complaint to the study protocol. ALF (Acute Liver failure) Classical Parkinsonism Atypical Parkinsonism Pregnancy Hypotension Uncontrolled hypertension CAD Psychiatric illness Acute episode of Hepatic encephlopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>